Stock Analiz

Fennec Pharmaceuticals Inc. FENC

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$11.62Market cap $410M
Open the interactive analysis →

Fennec Pharmaceuticals Inc. (FENC) is a healthcare company listed in the US with a market value of about $410M. In the twelve months to September 30, 2026 it had revenue of $66M and net income of $2M, a net margin of 3.1%.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (4/5); the weakest is shareholder returns (0/5).

Key numbers: a P/E of 387.3, 5-year revenue growth of 205% a year, a 5-year average ROIC of -39%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 104% above the current price.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $170000 in 2020 to $45M in 2025, growth of about 204.7% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 9% over three years (dilution for shareholders). It spends 1% of revenue on research and development.

Score: 1.6 / 5

Value1/5
Future growth2/5
Track record1/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)387.3
Forward P/E15.4
P/FCF—
P/S6.2
P/B8.3
EV/EBITDA94.6
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price+104%

Growth and quality

Revenue growth (1 yr)-6.1%
Revenue growth (5 yrs, per year)204.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-410.8%
ROIC (5-yr avg.)-39.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$66M$45M$48M$21M$2M—$170000$0$0$0$0
Net income$2M-$10M-$436000-$16M-$24M-$17M-$18M-$13M-$10M-$7M-$3M
Free cash flow———————————
EPS (diluted)$0.02$-0.34$-0.02$-0.60$-0.90$-0.67$-0.00$-0.64$-0.52$-0.47$-0.22
Net margin3.1%-21.8%-0.9%-75.5%-1544.9%—-10652.4%————
ROIC—-14.0%15.1%-52.2%-79.9%-65.5%-48.6%-86.5%-38.6%-26.0%-80.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $17.20, 48% above the current price; targets range from $16.00 to $18.00; the consensus rating is “Strong buy”; expected EPS is $0.30 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Fennec Pharmaceuticals’s P/E ratio?

About 387.3, based on the last twelve months of diluted earnings per share (forward P/E about 15.4).

Is Fennec Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 104% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Fennec Pharmaceuticals pay a dividend?

Not currently.

Is Fennec Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Fennec Pharmaceuticals scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.